Condition: Advanced Ovarian Carcinoma · Advanced Renal Cell Carcinoma · Advanced Pancreatic Carcinoma · Sponsor: Molecure S.A.
The goal of this clinical trial is to learn if the OATD-02 administration (orally) in monotherapy is safe and has the pharmacodynamic potential to restore and enhance tumour responses to immunotherapy through increased arginine levels or intrinsic anti-tumour activity in participants with advanced metastatic colorectal cancer, ovarian cancer, renal cancer or pancreatic cancer.
This description comes directly from the study's public registry record.
Clinical · 0048225526724 · clinical@molecure.com
Molecure SA · 0048225526724 · contact@molecure.com
Always discuss trial participation with your own doctor first.
| Site | Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland | Recruiting |
| Site | Otwock, Masovian Voivodeship, Poland | Recruiting |
| SIte | Warsaw, Masovian Voivodeship, Poland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05759923